Xequel Bio

Xequel Bio is a biotechnology company dedicated to revolutionizing the way wounds heal. Our aCT1 platform has unlimited potential to provide solutions for unmet needs across various therapeutic areas. Current focus areas include multiple indications in dermatology, ophthalmology, and pulmonology. By addressing the underlying pathophysiology of inflammation and injury-based medical conditions, Xequel Bio’s technology can offer doctors new treatment options to improve patient outcomes. Granexin Gel, our flagship product, is in the late-stage clinical trial phase. Also in clinical trials is iNexin®™ eye drops, while our inhalation solution is in advanced preclinical development. This innovative pipeline showcases the diverse applications of the aCT1 platform, and Xequel Bio is committed to bringing these applications to market to help those who can benefit from their use!